ATR kinase inhibitor AZD6738 potentiates CD8(+) T cell–dependent antitumor activity following radiation

DNA-damaging chemotherapy and radiation therapy are integrated into the treatment paradigm of the majority of cancer patients. Recently, immunotherapy that targets the immunosuppressive interaction between programmed death 1 (PD-1) and its ligand PD-L1 has been approved for malignancies including no...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:J Clin Invest
Autori principali: Vendetti, Frank P., Karukonda, Pooja, Clump, David A., Teo, Troy, Lalonde, Ronald, Nugent, Katriana, Ballew, Matthew, Kiesel, Brian F., Beumer, Jan H., Sarkar, Saumendra N., Conrads, Thomas P., O’Connor, Mark J., Ferris, Robert L., Tran, Phuoc T., Delgoffe, Greg M., Bakkenist, Christopher J.
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Society for Clinical Investigation 2018
Soggetti:
Research Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6118586/
https://ncbi.nlm.nih.gov/pubmed/29952768
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI96519
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi